Pharmacyclics cancer drug not approvable--US FDA
LOS ANGELES Dec 21 (Reuters) - Drug developer Pharmacyclics Inc (PCYC.O) said on Friday that the U.S. Food and Drug Administration turned down its application to market Xcytrin as a treatment for non-small cell lung cancer which has spread to the brain.
The company said in a statement that it continues to believe that Xcytrin is a novel active cancer drug and will seek a corporate partner to help support future development.
Pharmacyclics said it expects data in the first half of 2008 from three Phase 2 trials evaluating the drug in patients with advanced relapsed non-small cell lung cancer.
The company had been seeking approval for use of Xcytrin in combination with whole brain radiation therapy. (Reporting by Deena Beasley in Los Angeles; Editing by Gary Hill)
Trending On Reuters
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video